KabiCare provides support to help patients access STIMUFEND® (pegfilgrastim-fpgk)
Our experts work closely with you and your staff to help make every step smoother, including enrolling in KabiCare, navigating patient insurance coverage and financial assistance, access to medication, patient disease education, injection training, refill reminders, and more.
Enrollment support
Financial support*
Insurance support
Clinical support
*Eligibility criteria apply.
Resources for STIMUFEND
Healthcare Common Procedure Coding System (HCPCS) code
Payment status indicator
Identifies whether a service represented by a CPT or HCPCS code is payable under the Outpatient Prospective Payment System (OPPS). Ambulatory Payment Classification (APC) or another payment system. Only 1 status indicator is assigned to each CPT or HCPCS code.
Check with the specific payer to verify additional coding and billing requirements for STIMUFEND®.
Download the Billing and Coding Guide
- Filename
- STIMUFEND-Billing-and-Coding-Guide-3500.pdf
- Size
- 880 KB
- Format
Healthcare Common Procedure Coding System (HCPCS) code
Payment status indicator
Identifies whether a service represented by a CPT or HCPCS code is payable under the Outpatient Prospective Payment System (OPPS). Ambulatory Payment Classification (APC) or another payment system. Only 1 status indicator is assigned to each CPT or HCPCS code.
Download the Billing and Coding Guide
- Filename
- STIMUFEND-billing-and-coding-guide.pdf
- Size
- 1 MB
- Format
Dosing and Administration Guide
- Filename
- STIMUFEND-Dosing-and-Administration-Guide-3565.pdf
- Size
- 552 KB
- Format
HCP STIMUFEND Brochure
- Filename
- STIMUFEND-HCP-Brochure-2316.pdf
- Size
- 7 MB
- Format
Coding and Billing Guide
- Filename
- STIMUFEND-Billing-and-Coding-Guide-3500.pdf
- Size
- 880 KB
- Format
Sample Letter of Medical Necessity
- Filename
- STIMUFEND-Letter-of-Necessity-1940.docx
- Size
- 30 KB
- Format
- docx
Sample Letter of Appeals
- Filename
- STIMUFEND-Letter of Appeal-1941.docx
- Size
- 32 KB
- Format
- docx
Experiencing a problem?
Fresenius Kabi may offer healthcare professionals a replacement for a STIMUFEND product that has been rendered unusable through unintentional, unplanned circumstances, including:
- Product was mishandled, dropped, broken, used, or stored incorrectly
- An unforeseen event caused damage to the product
- There was an error in mixing or preparing the product
To request a replacement, download the Product Replacement Form or call Fresenius Kabi’s customer service line at (888) 386-1300.
Fresenius Kabi reserves the right to reject a request for a product replacement in accordance with its STIMUFEND product replacement policy. Product dispensed through a specialty pharmacy is not eligible for product replacement. Additional eligibility requirements and limitations apply. See Product Replacement Form for more details.
Ready to start the conversation?
An Account Manager is your best source for learning more about STIMUFEND. Connect with your Account Manager to schedule a meeting, ask questions, receive in-depth product information, or request formulary data for your patients.
Important Safety Information
Contraindication
- Stimufend (pegfilgrastim-fpgk) is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products
- Reactions have included anaphylaxis
Splenic Rupture
- Splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim products
- Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain
Acute Respiratory Distress Syndrome (ARDS)
- ARDS can occur in patients receiving pegfilgrastim products
- Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving Stimufend
- Discontinue Stimufend in patients with ARDS
Serious Allergic Reactions
- Serious allergic reactions, including anaphylaxis, can occur in patients receiving pegfilgrastim products
- The majority of reported events occurred upon initial exposure and can recur within days after the discontinuation of initial anti-allergic treatment
- Permanently discontinue Stimufend in patients with serious allergic reactions
Use in Patients with Sickle Cell Disorders
- In patients with sickle cell trait or disease, severe and sometimes fatal sickle cell crises can occur in patients receiving pegfilgrastim products
- Discontinue Stimufend if sickle cell crisis occurs
Glomerulonephritis
- Has occurred in patients receiving pegfilgrastim products
- Diagnoses based on azotemia, hematuria, proteinuria, and renal biopsy
- Generally, events resolved after dose-reduction or discontinuation of pegfilgrastim products
- If suspected, evaluate for cause and if cause is likely, consider dose-reduction or interruption of Stimufend
Leukocytosis
- Increased white blood cell counts of 100 x 109/L have been observed
- Monitoring of complete blood count (CBC) during Stimufend therapy is recommended
Thrombocytopenia
- Thrombocytopenia has been reported in patients receiving pegfilgrastim products. Monitor platelet counts
Capillary Leak Syndrome (CLS)
- CLS has been reported after G-CSF administration, including pegfilgrastim products
- Characterized by hypotension, hypoalbuminemia, edema and hemoconcentration
- Episodes vary in frequency, severity and may be life-threatening if treatment is delayed
- Patients with symptoms should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care
Potential for Tumor Growth Stimulatory Effects on Malignant Cells
- G-CSF receptor has been found on tumor cell lines
- The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded.
Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Breast and Lung Cancer
- MDS and AML have been associated with the use of pegfilgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings.
Aortitis
- Aortitis has been reported in patients receiving pegfilgrastim products. It may occur as early as the first week after start of therapy
- Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count)
- Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue Stimufend if aortitis is suspected
Nuclear Imaging
- Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results
Most common adverse reactions
- Bone pain
- Pain in extremity
Indications and Usage
Stimufend is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Stimufend is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).
Limitations of Use
Stimufend is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Please see Stimufend Full Prescribing Information.
Stimufend Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only.
Indications
Stimufend is indicated to:
- Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia
- Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome)
Limitations of Use
Stimufend is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.